. 2016 Jan 20;2016:9507563. doi: 10.1155/2016/9507563

Table 4.

The effect of DLD and DHD doses on caspase-3, TNFα, and NFκB immune expressions.

Group	Caspase-3	TNFα	NFκB
Control	0.42 ± 0.80	0.40 ± 0.78	0.40 ± 0.88
DLD	0.60 ± 0.88	0.60 ± 0.80	0.60 ± 0.80
DHD	0.40 ± 0.40	2.40 ± 0.40	0.40 ± 0.40
DOX	58.60 ± 8.90^a	80.60 ± 8.90^a	58.60 ± 8.90^a
DOX/DLD	30.20 ± 7.90^a/b	35.20 ± 7.90^a/b	25.20 ± 7.90^a/b
DOX/DHD	10.00 ± 6.90^b	5.00 ± 4.90^b	10.00 ± 6.90^b

Animal groups tested are control untreated group, animals treated with low or high doses of DIA alone (DLD or DHD), respectively, and animals treated with DOX or with DOX together with low or high dose of DIA (DOX/DLD or DOX/DHD), respectively.

^aSignificant from control group; ^bsignificant from doxorubicin group.